Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Andexanet alfa for acute major bleeding episodes requiring reversal of anticoagulation, including reversal of factor Xa inhibition – first line. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2016 Authors' objectives Anticoagulants are drugs which prevent the blood from clotting. This can be important for the treatment of some patients, but it also increases the risks of bleeding, which can be very serious or even life-threatening. Andexanet alfa reverses the effects of anticoagulants, allowing the blood to clot normally again in an emergency.
Andexanet alfa is injected directly into the bloodstream of patients who are taking anticoagulants and bleeding.
Andexanet alfa is currently being studied to see how well it works and whether it is safe to use. If andexanet alfa is licensed in the UK, it will offer a new treatment for people with serious bleeding while taking anticoagulants. Indexing Status Subject indexing assigned by CRD MeSH Blood Coagulation; Blood Coagulation Factor Inhibitors; Factor Xa; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Humans Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NIHR Horizon Scanning Research&Intelligence Centre, University of Birmingham, Institute of Applied Health Research, Public Health building, Edgbaston, Birmingham B15 2TT
Tel: 0121 414 9077 Email: nihrhsc@contacts.bham.ac.uk AccessionNumber 32016000638 Date abstract record published 19/04/2016 |
